Fresenius Medical Care (NYSE: FMS; Frankfurt Stock Exchange: FME) has started selling its multiFiltratePRO kidney replacement system to U.S. hospital intensive care units. The launch, announced in a company press release on October 21, 2026, follows FDA action two days earlier on the machine and the two solutions that run through it.

The pitch is simplicity. The citrate and calcium pumps are built into the machine, so ICU teams no longer have to rig separate external infusion pumps. Infusion rates adjust automatically as blood and fluid flow change.

For investors, it is a real but modest product story, and it arrives ten days into a new CEO’s tenure.

What the FDA Signed Off On

There were three decisions, all dated October 19, according to the release. The FDA cleared the multiFiltratePRO System, which is a device. It approved Cienby, a sodium citrate solution, and Calrezdy, a calcium chloride solution, which are drugs.

Device clearance and drug approval are separate regulatory tracks. The release bundles them, and it does not say which device pathway the clearance used.

The labels are narrow. Both solutions are indicated for regional citrate anticoagulation during two specific modes of continuous dialysis, CVVHD and CVVHDF, in adults and pediatric patients weighing at least 40 kg. The machine is cleared for patients of 40 kg or more with acute renal failure.

Why Citrate Matters in the ICU

Acute kidney injury (AKI) is a sudden loss of the kidneys’ ability to filter waste from the blood. In the sickest ICU patients, doctors often turn to continuous kidney replacement therapy (CKRT), a slow form of dialysis that runs around the clock.

The problem is clotting. Blood flowing through an external filter wants to clot, and a clotted filter means stopped treatment. The two main fixes are systemic heparin, a blood thinner that affects the whole body, or regional citrate anticoagulation (RCA).

Citrate works locally. It is added to the blood before the filter, where it binds calcium, a key ingredient in clotting. Calcium is then added back before the blood returns to the patient. The catch is the arithmetic. Get the ratio wrong and calcium swings too high or too low. Fresenius says its integrated pumps and Ci-Ca protocol handle that math.

The “First” Claim Needs an Asterisk

Fresenius calls this the first CKRT system and dedicated solutions package available in the U.S. for on-label RCA using its Ci-Ca protocol. “On-label” is doing a lot of work in that sentence.

The release does not mention that multiFiltrate PRO has been in U.S. hospitals before. In April 2020, during COVID-19, the FDA granted Fresenius an Emergency Use Authorization (EUA) for the multiFiltrate PRO System and its multiBic/multiPlus solutions. Baxter received a separate EUA that August for Regiocit, a citrate replacement solution, which Baxter noted at the time was not FDA-approved.

Both authorizations were revoked on January 16, 2025, at the companies’ own request, after each told the FDA it no longer planned to offer the products under emergency use.

The fair reading: it appears to be the first full, non-emergency FDA green light for an integrated citrate CKRT package. It is not the first time U.S. intensive care units have used citrate anticoagulation, or this machine. BioTech Stocks Daily found nothing contradicting that narrower version of the claim.

What the Evidence Shows, and What It Doesn’t

The release leans on a single study, the RICH trial, published in JAMA in 2020. It randomized 638 critically ill AKI patients across 26 German centers, and 596 completed it. Median filter life was 47 hours with citrate versus 26 hours with heparin. Bleeding complications were lower with citrate, at 5.1% versus 16.9%.

The release does flag that the trial was underpowered on mortality. It was stopped early, and 90-day death rates (51.2% vs. 53.6%) did not differ significantly. What the release leaves out is that new infections were more common in the citrate group, 68.0% versus 55.4%.

Two more caveats. RICH compared anticoagulation strategies, not specific machines. And its lead investigator had reported grants and personal fees from Fresenius, as well as grants from Baxter, according to conference coverage of the results.

The Safety Fine Print

Cienby causes low blood calcium by design. Its label warns that severe hypocalcemia can trigger arrhythmia, cardiac arrest, seizure and coma. It can also cause high sodium, low magnesium and acid-base problems, and citrate can build up in patients with liver impairment or shock.

The most common adverse reactions, each above 5%, were high calcium, high sodium, low calcium and metabolic alkalosis. Calrezdy carries its own warnings on arrhythmia and low blood pressure, with ECG monitoring recommended. Neither solution has established safety or effectiveness in patients under 40 kg.

Who Fresenius Is Up Against

Baxter has long been a major name in U.S. CKRT. Its 2020 EUA announcement listed PrisMax and Prismaflex as its CRRT control units. Baxter no longer owns it. The $3.80 billion sale of its Kidney Care unit to Carlyle closed on January 31, 2025, and that unit, now called Vantive, includes CRRT. Vantive is private, so the main incumbent has no public ticker.

The launch also follows a familiar Fresenius pattern. Its 5008X CAREsystem won its first FDA 510(k) clearance in February 2024 and an updated clearance in May 2025, with a full-scale U.S. commercial launch planned for 2026. Joe Turk, CEO of the company’s Care Enablement unit, said multiFiltratePRO “expands the options available to critical care teams.”

On the leadership side, Shervin J. Korangy took over as Fresenius Medical Care’s CEO on October 12, 2026, succeeding Helen Giza.

What Wasn’t Disclosed

The release gives no pricing, no sales or revenue targets tied to the product, and no count of hospitals in the initial rollout. It says only that the launch starts as a controlled rollout before moving to full availability, with no dates attached. It also offers no head-to-head data against competing CKRT systems.

This article covers a regulatory and commercial milestone and is not medical or investment advice.

Sources

• Fresenius Medical Care: Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO, PRNewswire, October 21, 2026. Primary source release.
• Federal Register: Revocation of Emergency Use of a Drug Product During the COVID-19 Pandemic (FDA-2025-N-0874), cited for the 2020 EUAs for multiFiltrate PRO and Baxter’s Regiocit and their January 16, 2025 revocation, neither of which appeared in the Fresenius release.
• Baxter: Baxter Obtains U.S. FDA Emergency Use Authorization for Regiocit Replacement Solution Used in CRRT, cited for Regiocit’s unapproved EUA status and Baxter’s PrisMax and Prismaflex CRRT units.
• JAMA (via PubMed): Effect of Regional Citrate Anticoagulation vs Systemic Heparin Anticoagulation During Continuous Kidney Replacement Therapy (RICH trial), cited for full trial results, including the infection finding the release did not mention.
• Medicom / Reuters Health: Kidney Week 2020 coverage of the RICH trial, cited for the lead investigator’s reported financial relationships with Fresenius and Baxter.
• Baxter International Form 10-K for fiscal 2024 (SEC EDGAR), cited for the completed sale of Baxter’s Kidney Care business (Vantive) to Carlyle.
• Fresenius Medical Care: Fresenius Medical Care Begins Broader U.S. Commercialization of 5008X CAREsystem, cited for the 5008X clearance history and 2026 launch plan.
• Fresenius Medical Care: Shervin J. Korangy Appointed CEO of Fresenius Medical Care, cited for the October 12, 2026 CEO transition.

Editorial Disclosure

This article reports on the U.S. launch of the multiFiltratePRO System and the FDA clearance and approvals announced by Fresenius Medical Care in a press release issued on October 21, 2026. Securities and corporate structures discussed: Fresenius Medical Care AG (NYSE: FMS; Frankfurt Stock Exchange: FME). Also referenced: Baxter International Inc. (NYSE: BAX) and The Carlyle Group Inc. (Nasdaq: CG), the owner of privately held Vantive. BioTech Stocks Daily has not received, nor will it accept, any compensation, direct or indirect, from Fresenius Medical Care, Baxter, Carlyle, Vantive, or any other corporate or third-party sponsor for the preparation or publication of this coverage. No staff member, principal, or affiliate of BioTech Stocks Daily holds a position, option, or financial interest in any of the securities mentioned as of the date of publication. The product’s prior Emergency Use Authorization history, the RICH trial data, the competitive landscape, and the corporate context were drawn from the independent sources cited above, since the original release did not address them. Statements regarding the pace of the U.S. rollout, future commercial availability, product adoption, competitive positioning, and the company’s strategic direction are forward-looking statements. They involve substantial risks, regulatory uncertainties, and commercial variables; actual results may differ materially. Medical technology and healthcare investments carry significant financial risk, including regulatory action, product recalls, reimbursement changes, and market competition, which can result in the loss of invested capital. This article is published strictly for independent news reporting, market context, and educational purposes only. It does not constitute an investment recommendation, endorsement, or professional financial, legal, or tax advice. Furthermore, this content is not medical advice; patients and healthcare providers should consult appropriate clinical professionals for medical guidance, including the full Prescribing Information for Cienby and Calrezdy.

For full details regarding our editorial independence, publishing policies, and comprehensive risk disclaimers, please see our full DISCLAIMER.